BridgeBio Pharma, Inc. Proceeds from Sale and Maturity of Marketable Securities
BridgeBio Pharma, Inc. (BBIO) reported Proceeds from Sale and Maturity of Marketable Securities of $0 for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2025-08-05
- BridgeBio Pharma, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2024-12-31 was $0.00.
- BridgeBio Pharma, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2024-09-30 was $40.00M, a 2.44% decline year-over-year.
- BridgeBio Pharma, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2024-06-30 was $55.00M, a 133.55% increase year-over-year.
- BridgeBio Pharma, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- BridgeBio Pharma, Inc. proceeds from sale and maturity of marketable securities for fiscal 2024 was $95.00M, a 15.08% increase from fiscal 2023.
- BridgeBio Pharma, Inc. proceeds from sale and maturity of marketable securities for fiscal 2023 was $82.55M, a 82.79% decline from fiscal 2022.
- BridgeBio Pharma, Inc. proceeds from sale and maturity of marketable securities for fiscal 2022 was $479.69M, a 26.17% increase from fiscal 2021.
- BridgeBio Pharma, Inc. proceeds from sale and maturity of marketable securities for fiscal 2021 was $380.20M, a 52.61% increase from fiscal 2020.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2025-06-30 | $0.00 10-Q · filed 2025-08-05 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $40.00M derived: sum of 2 quarters · filed 2025-02-20 | $95.00M derived: sum of 3 quarters · filed 2025-08-05 | $95.00M 10-K · filed 2025-02-20 |
| 2024-09-30 | $40.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $95.00M derived: sum of 2 quarters · filed 2025-08-05 | $95.00M 10-Q · filed 2024-11-12 | $95.00M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-06-30 | $55.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $55.00M 10-Q · filed 2025-08-05 | $55.00M derived: sum of 3 quarters · filed 2025-08-05 | $96.00M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-02 | $0.00 derived: sum of 2 quarters · filed 2025-02-20 | $41.00M derived: sum of 3 quarters · filed 2025-02-20 | $64.55M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $41.00M derived: sum of 2 quarters · filed 2025-02-20 | $64.55M derived: sum of 3 quarters · filed 2025-02-20 | $82.55M 10-K · filed 2025-02-20 |
| 2023-09-30 | $41.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $64.55M derived: sum of 2 quarters · filed 2024-11-12 | $82.55M 10-Q · filed 2024-11-12 | $109.42M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $23.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $41.55M 10-Q · filed 2024-08-01 | $68.42M derived: sum of 3 quarters · filed 2025-02-20 | $227.32M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $18.00M 10-Q · filed 2024-05-02 | $44.87M derived: sum of 2 quarters · filed 2025-02-20 | $203.77M derived: sum of 3 quarters · filed 2025-02-20 | $310.99M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $26.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $185.77M derived: sum of 2 quarters · filed 2025-02-20 | $292.99M derived: sum of 3 quarters · filed 2025-02-20 | $479.69M 10-K · filed 2025-02-20 |
| 2022-09-30 | $158.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $266.12M derived: sum of 2 quarters · filed 2023-11-02 | $452.82M 10-Q · filed 2023-11-02 | $527.82M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $107.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $293.92M 10-Q · filed 2023-08-03 | $368.92M derived: sum of 3 quarters · filed 2024-02-22 | $435.19M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $186.69M 10-Q · filed 2023-05-04 | $261.69M derived: sum of 2 quarters · filed 2024-02-22 | $327.96M derived: sum of 3 quarters · filed 2024-02-22 | $467.69M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $75.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $141.27M derived: sum of 2 quarters · filed 2024-02-22 | $281.00M derived: sum of 3 quarters · filed 2024-02-22 | $380.20M 10-K · filed 2024-02-22 |
| 2021-09-30 | $66.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $206.00M derived: sum of 2 quarters · filed 2022-11-03 | $305.20M 10-Q · filed 2022-11-03 | $415.32M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $139.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $238.93M 10-Q · filed 2022-08-04 | $349.06M derived: sum of 3 quarters · filed 2023-02-23 | $405.56M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $99.20M 10-Q · filed 2022-05-05 | $209.32M derived: sum of 2 quarters · filed 2023-02-23 | $265.82M derived: sum of 3 quarters · filed 2023-02-23 | $305.84M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $110.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $166.62M derived: sum of 2 quarters · filed 2023-02-23 | $206.64M derived: sum of 3 quarters · filed 2023-02-23 | $249.14M 10-K · filed 2023-02-23 |
| 2020-09-30 | $56.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $96.52M derived: sum of 2 quarters · filed 2021-11-04 | $139.02M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $40.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $82.52M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $42.50M 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |